RISK ASSESSMENT RECORD FORM

Please refer to the accompanying guidance when completing this form

Section 1: Administrative Details

Name of Assessor:	Job Title:	Date of Assessment:

Section 2: Activity/Task

Activity /Task
Provision of an MRI service

Risk:
Adverse reaction to MRI contrast agents

Area affected:
MRI

Source of Risk(Background):
MRI contrast agents are often administered intravenously to patients as part of their MRI scan. These agents are most commonly based on gadolinium chelates. A very small proportion of people will experience an adverse reaction to these contrast agents. This is usually minor, but in rare cases a severe anaphylactic reaction may occur. Additionally, Nephrogenic Systemic Fibrosis (NSF) has been associated with some intravenous gadolinium-containing magnetic resonance imaging (MRI) contrast agents in patients with severe renal impairment. There is also growing evidence for accumulation of gadolinium in the brain following repeated administration of these agents, the clinical significance of which is unclear.

Supporting Evidence:
MHRA guidance on the administration of MRI contrast agents [1].

Factors the risk contains: *(if for COSHH include route of exposure, length of exposure time and exposure limits)*
- patient renal function

Potential Consequence if risk is realised:
Adverse reaction, risk of NSF

Section 3: Current Control Measures

Local guidelines have been drawn up by a consultant radiologist, in conjunction with renal physicians, on when to administer contrast agent, taking into account patient's GFR.

MRI safety screening form includes a question specifically about known kidney problems.

MR staff are trained in responding to anaphylactic reactions.

Section 4: Risk Rating
Use the consequence, likelihood and risk score tables in the accompanying guidance to identify the scores below.

Consequence Score:

Likelihood Score:

Risk Score:

Initial Risk Grading:

Section 5: Risk Reduction Options		
Options	Revised Risk Score	Cost
No further reduction needed		

Section 6: Directorate/Divisional Agreed Actions		
Actions	Lead	Target Date

Section 7: Risk Grading				
	Consequence	**Likelihood**	**Score**	**Grade**
Initial:				
Current (will be the same as initial to begin with):				
Residual:				

Section 8: Review
Risk Owner:
Planned Review Date:

Reference

[1] D. Grainger, “Safety Guidelines for Magnetic Resonance Imaging Equipment in Clinical Use,” Medicines and Healthcare Products Regulatory Agency, Mar. 2015.